FDA Panel Supports Painkiller Research

Good news for severe arthritis and chronic back pain suffers. The FDA’s Arthritis Advisory Committee has voted 21-0 to recommend continued development of an experimental class of painkillers for arthritis, despite links to bone decay and joint failure. Studies on the class of drugs known as anti-nerve growth factor drugs, designed to treat osteoarthritis and chronic back pain, were halted in 2010 after the joint problems were reported. All trials were stopped except those in cancer pain. The FDA advisory… [more]